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Novel parent-of-origin-specific differentially
methylated loci on chromosome 16
Katharina V. Schulze1†, Przemyslaw Szafranski1†, Harry Lesmana2, Robert J. Hopkin2, Aaron Hamvas3,
Jennifer A. Wambach4, Marwan Shinawi5, Gladys Zapata6, Claudia M. B. Carvalho1, Qian Liu1, Justyna A. Karolak1,
James R. Lupski1,6,7, Neil A. Hanchard1,8*† and Paweł Stankiewicz1*†

Abstract
Background: Congenital malformations associated with maternal uniparental disomy of chromosome 16, upd(16)mat,
resemble those observed in newborns with the lethal developmental lung disease, alveolar capillary dysplasia with
misalignment of pulmonary veins (ACDMPV). Interestingly, ACDMPV-causative deletions, involving FOXF1 or its lungspecific upstream enhancer at 16q24.1, arise almost exclusively on the maternally inherited chromosome 16. Given the
phenotypic similarities between upd(16)mat and ACDMPV, together with parental allelic bias in ACDMPV, we
hypothesized that there may be unknown imprinted loci mapping to chromosome 16 that become functionally
unmasked by chromosomal structural variants.
Results: To identify parent-of-origin biased DNA methylation, we performed high-resolution bisulfite sequencing of
chromosome 16 on peripheral blood and cultured skin fibroblasts from individuals with maternal or paternal upd(16)
as well as lung tissue from patients with ACDMPV-causative 16q24.1 deletions and a normal control. We identified 22
differentially methylated regions (DMRs) with ≥ 5 consecutive CpG methylation sites and varying tissue-specificity,
including the known DMRs associated with the established imprinted gene ZNF597 and DMRs supporting maternal
methylation of PRR25, thought to be paternally expressed in lymphoblastoid cells. Lastly, we found evidence of
paternal methylation on 16q24.1 near LINC01082 mapping to the FOXF1 enhancer.
Conclusions: Using high-resolution bisulfite sequencing to evaluate DNA methylation across chromosome 16, we
found evidence for novel candidate imprinted loci on chromosome 16 that would not be evident in array-based assays
and could contribute to the birth defects observed in patients with upd(16)mat or in ACDMPV.
Keywords: Imprinting, CpG, Trisomy 16, Uniparental disomy 16, ACDMPV

Introduction
Trisomy 16, the most frequent prenatally detected trisomy [1], is embryonic lethal unless rescued during early
embryogenesis. Maternal uniparental disomy of chromosome 16, upd(16)mat, in humans is among the most
commonly identified chromosomal UPDs [2, 3], typically
arising during embryonic development after the paternal
chromosome is lost, which occurs in a third of all trisomy
16 rescue events. upd(16)mat has been associated with
intrauterine growth restriction (IUGR) and a variety of
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congenital malformations, including heart defects, pulmonary hypoplasia, tracheoesophageal fistula, gut malrotation, absent gall bladder, renal agenesis, hydronephrosis,
imperforate anus, and single umbilical artery [2]. Of these
clinical features, IUGR has been most often attributed to
confined placental trisomy 16, although growth restrictions and short stature have been reported in association
with other chromosomal UPDs, including the first human
case [4], whereas the other phenotypic features have been
suggested to result from upd(16) or embryonic mosaic
trisomy 16 [5–9].
Trisomy 16 is most often the result of maternal meiosis I nondisjunction; consequently, most upd(16)mat
cases are heterodisomic, retaining both distinct maternal
copies of chromosome 16 after trisomic rescue. Whereas
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genetic recombination between the homologous chromosomes can result in regions of homozygosity with
the potential to unmask recessive disorders [10], the
vast majority of homologous loci mapping to chromosome 16 in upd(16)mat are non-identical [11]. Consequently, the clinical phenotypes associated with
upd(16)mat are likely the result of unbalanced expression of imprinted genes. In contrast, the very rare paternal uniparental disomy of chromosome 16,
upd(16)pat, has been associated with a relatively benign clinical phenotype attributed to duplication of
the paternal chromosome as a means of rescuing maternal
nullisomy 16. Since most upd(16)pat cases are isodisomic,
gene-dosage dependent congenital malformations found
in upd(16)pat are typically attributed to unmasked mutations in recessive disease genes [12].
Genome-wide searches for imprinted regions in different
tissues have been performed through DNA sequence-based
computational predictions [13], gene expression assays
[14–18], DNA methylation analyses [19–23], and combinations thereof [24]. The imprinted locus, most consistently
identified as such on chromosome 16, is the paternally
imprinted (maternally expressed) ZNF597 gene, which encodes a zinc finger protein. While the biological function of
ZNF597 is unknown, Inoue et al. [25] have suggested that
its overexpression might contribute to some of the clinical
phenotypes associated with upd(16)mat.
Interestingly, with the exception of IUGR, many of the
clinical features seen in patients with upd(16)mat have
often been observed also in children with the neonatal lethal lung developmental disorder, alveolar capillary dysplasia with misalignment of pulmonary veins (ACDMPV,
MIM #265380) [26]. Aside from pulmonary hypoplasia, the
malformations observed both in infants with ACDMPV
and upd(16)mat affect the respiratory system (e.g., tracheoesophageal fistula, tracheal narrowing), gastrointestinal system (e.g., intestinal malrotation, omphalocele,
gastrointestinal atresias, imperforate anus), the cardiovascular system (e.g., ventricular and atrial septal defects, coarctation of the aorta), and the genitourinary system (e.g.,
hydronephrosis, hydroureter, hypospadias) [7, 27–29].
ACDMPV is caused by mutations or copy-number variant
(CNV) deletions involving the FOXF1 locus at 16q24.1 [29,
30]. Interestingly, deletions of the FOXF1 upstream enhancer have been found almost exclusively on the maternally
inherited chromosome 16 [31, 32]. Given the parental allelic
bias in ACDMPV as well as the phenotypic differences between maternal and paternal upd(16), we hypothesized that
there may be unknown imprinted or partially imprinted loci
mapping to chromosome 16q24.1 that contribute to the observed key clinical phenotypic features of both upd(16)mat
and ACDMPV.
To investigate this hypothesis and to identify novel differentially methylated regions (DMRs), we assessed DNA
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methylation at CpG dinucleotides across chromosome 16
using capture-based targeted bisulfite sequencing in samples with maternal and paternal upd(16) and large heterozygous deletions at 16q23.3q24.1.

Methods
Subjects

Peripheral blood samples were obtained from two individuals with upd(16)mat, two with upd(16)pat, and two normal controls. Both upd(16)mat blood samples were largely
heterodisomic in the pericentromeric regions with distal
isodisomies on both chromosome arms, while both
upd(16)pat samples were suspected to be fully isodisomic
(Additional file 1: Table S1). There was no evidence for
mosaic trisomy 16 using chromosomal microarray, karyotyping, or exome analyses in one upd(16)mat proband.
The placenta for the same upd(16)mat proband was noted
to be small, but no cytogenetic analyses were performed
to test for trisomy 16. Information regarding trisomy 16
testing was not available for the remaining upd(16) cases.
DNA was extracted from blood using Gentra Puregene
Kit (Qiagen, Germantown, CA, USA).
Skin fibroblasts were collected from two additional individuals with upd(16)mat and two additional normal
controls. The upd(16)mat sample that passed subsequent
quality measures was heterodisomic in the pericentromeric regions with one or two distal isodisomies (Additional file 1: Table S1). No evidence of trisomy 16 was
detected in this proband using fluorescence in situ
hybridization (FISH); however, FISH analysis of placental
tissue indicated confined placental trisomy 16 mosaicism. Fibroblasts were cultured in Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 10% fetal
bovine serum (FBS). Fibroblast DNA was extracted using
the Gentra Puregene Kit (Qiagen).
Autopsy lung tissue samples were obtained from two
ACDMPV individuals with heterozygous CNV deletions
(86,505,450-86,575,461 and 83,673,382-86,298,284, GRCh37/
hg19) on the maternally inherited chromosome 16 and one
age-matched control individual with a medical condition unrelated to lung development. DNA was extracted from
frozen lung tissues using DNeasy Blood and Tissue
Kit (Qiagen). Detailed patient information was previously published [12, 29, 32, 33] or can be found in
the Additional file 2.
Bisulfite sequencing

Bisulfite sequencing of chromosome 16 was performed according to manufacturer’s instructions (protocol v1.1) using
a custom SeqCap Epi Enrichment Kit (Roche NimbleGen,
Madison, WI, USA) designed to capture 74.1–85.6% of CpG
sites on chromosome 16. Briefly, 1 μg of genomic DNA was
fragmented using a Covaris Ultra Sonicator (Covaris Inc.,
Woburn, MA, USA) to a size range of 180–220 bp.
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Following DNA fragmentation, sample libraries were prepared using the KAPA Library Preparation Kit for Illumina
Platforms (Kapa Biosystems, Boston, MA, USA), according
to manufacturer’s protocol v2.14. DNA was subjected to
end repair, A-tailing, and adapter ligation on SeqCap EZ
Purification Beads (Roche NimbleGen). Post-ligation
cleanup was performed using AMPure XP Beads (Agencourt, Beverly, MA, USA). DNA sample libraries were bisulfite converted using EZ DNA Methylation-Lightning Kit
(Zymo Research, Irvine, CA, USA) at 98 °C for 8 min,
followed by 60 min incubation at 54 °C, and purification on
Zymo Spin IC columns. Bisulfite-converted sample libraries
were amplified using pre-capture ligation-mediated polymerase chain reaction (LM-PCR) and purified using
AMPure XP Beads (Agencourt). The quality of the amplified
bisulfite-converted sample libraries was checked on Bioanalyzer 2100 using DNA 1000 chip (Agilent Technologies,
Santa Clara, CA, USA). One microgram of the amplified
bisulfite-converted sample libraries was then hybridized to
SeqCap Epi Probe Pool (Roche NimbleGen) at 47 °C for
64 h. Captured bisulfite-converted samples were washed
and recovered using SeqCap Pure Capture Beads (Roche
NimbleGen) and subsequently amplified using LM-PCR.
Purification of the amplified and captured bisulfite-converted
DNA samples was performed using AMPure XP Beads
(Agencourt) followed by quantification and quality assessment using a Bioanalyzer DNA 1000 chip (Agilent Technologies). The captured and amplified DNA fragments were
then sequenced using 100 bp paired-end reads on the Illumina HiSeq 2000 platform (Illumina Inc., San Diego, CA,
USA), multiplexed to up to six samples per lane.
Data preprocessing

Samples were demultiplexed using Casava (v1.8, Illumina).
Thereafter, Bismark (v0.12.3) [34] was used to (1) align
FASTQ files to the hg19 reference genome, (2) remove
duplicate reads, (3) trim five bases off the 5′ ends of all
reads and one base off the 3′ end of “read 2” paired reads
in order to eliminate known methylation biases, and (4)
extract counts of methylated and unmethylated cytosines
found on the forward and reverse strand in a CpG dinucleotide context.
Peripheral blood-based data analysis

Methylated and unmethylated cytosine counts for each sample were loaded into the R software environment (v3.4.4). To
increase coverage, counts at the same locus were pooled for
all peripheral blood samples of the same disomy category,
upd(16)mat, upd(16)pat, and biparental control, and only
those loci represented in all categories were used for subsequent analyses. An absolute difference in percent methylation of ≥ 40 between maternal and paternal upd(16) and an
intermediate methylation in control (biparental) samples
(upd(16)mat > biparental > upd(16)pat or upd(16)mat <
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biparental < upd(16)pat) at individual loci was considered
evidence of parent-of-origin biases in methylation. Adjacent
differentially methylated loci with the same direction of effect
were considered as regions; neighboring regions that were
separated by only one discordant methylation site were combined into one region. Regions with a median coverage < 10×
in any sample category were removed, as were those with an
absolute difference in percent methylation > 50 between
samples of the same category, if they had a median coverage
> 3×. Results from peripheral blood samples were then compared to DNA methylation of fibroblast cells and three lung
tissue samples.
Lung tissue-based data analysis

Since maternal and paternal upd(16) lung tissue samples
were not available, ACDMPV samples with deletions of the
maternal 16q23.3q24.1 allele were used instead to study
parent-of-origin biases in methylation based on the
remaining, hemizygous, paternal alleles. Percent methylation
was compared at CpG methylation sites that were captured
at least once per sample across each deleted locus. For this
analysis, an absolute difference in percent methylation ≥ 20
between the hemizygous ACDMPV sample and each dizygotic control was considered suggestive of parent-of-origin
biases in methylation. Adjacent CpG methylation sites that
matched this criterion and had the same direction of effect
were collapsed into regions; regions containing at least five
differentially methylated cytosines and a median coverage of
7× were considered candidate loci for parent-of-origin
biased DNA methylation. In comparison to the 10× coverage threshold from the blood-based analysis, this more lenient coverage filter was chosen to account for the fact that
samples were not collapsed by case/control-status in the
lung-based analysis.
Variant calling

Single nucleotide variants (SNVs) were called from
aligned, coordinate-sorted, and deduplicated BAM files
using Bis-SNP (v1.0.0) [35]. The software’s BisulfiteGenotyper was supplied with the hg19 reference genome
and a variant file of common single nucleotide polymorphisms (dbSNP build 151). Raw SNV calls were then filtered using Bis-SNP’s VCFpostprocess, with default
parameters, to produce a final list of SNVs for each sample. To identify regions of homozygosity for the purpose
of gauging hetero- and isodisomy, the resulting variant
call files (VCFs) were run through the bcftools roh algorithm (v1.8) with the parameters -G30 and --AF-dflt 0.4.
The only samples to include at least one region of
homozygosity larger than 10 Mb, indicative of isodisomy
[36], were both upd(16)pat peripheral blood samples and
one upd(16)mat fibroblast sample that passed filtering
thresholds.
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Results
Bisulfite sequencing in upd(16) samples confirms and
expands differential methylation of CpGs at known
imprinted regions

We performed chromosome 16-wide targeted capture-based
bisulfite sequencing on DNA samples extracted from the
peripheral blood of two individuals with upd(16)mat, two
with upd(16)pat, and two normal controls. In addition, we
used the same bisulfite sequencing approach on skin fibroblast DNA obtained from two individuals with upd(16)mat
and two healthy controls; however, only one fibroblast sample, upd(16)mat, passed our quality control filters. Consequently, in our subsequent analyses, we primarily compared
DNA methylation between different UPD states in peripheral
blood samples and then juxtaposed the identified methylation patterns alongside those in the fibroblast upd(16)mat
sample. By collapsing the sequencing reads of peripheral
blood samples within each category to strengthen depth
of coverage, we were able to capture 1,690,963 forward
and reverse strand CpG cytosines that were covered in all
sample groups. In contrast to the widely used Illumina
Infinium 450 K and EPIC methylation arrays, which, respectively, target 2.0% and 3.4% of CpGs on chromosome
16, our approach allowed us to assess DNA methylation at
a much higher resolution by capturing 76.7% of CpG sites
(Additional file 2: Fig. S1).
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We then searched for parent-of-origin biases in
methylation, which we defined as an absolute difference
in percent methylation of at least 40 between
upd(16)mat and upd(16)pat with intermediate methylation in control samples. Among the 25,105 CpG methylation sites matching these criteria, we found 14
genomic regions with a median read coverage ≥ 10× and
at least five adjacent differentially methylated cytosines
with evidence of parent-of-origin biased methylation
(Table 1, Fig. 1a, Additional file 1: Table S2, Additional file
2: Fig. S2). The three regions containing most of the differentially methylated cytosines coincided with the known
chromosome 16 imprinted gene ZNF597 (Fig. 1b)—two
with the paternally methylated region intergenic to ZNF597
and NAA60 on 16p13.3, methylation at which serves as a
bidirectional repressor [20], and the other with the maternally methylated region telomeric to ZNF597 [21]. Lastly,
we identified an additional, smaller maternally methylated
region in the last exon of ZNF597, which has not been previously described. This region might have escaped prior detection due to the absence of overlapping Infinium
methylation array probes or the relatively low CpG density.
Methylation at these imprinted regions showed the same
parent-of-origin biased pattern in the upd(16)mat fibroblast
sample, suggesting that the methylation patterns at these
imprinted regions are conserved across tissues.

Table 1 Genomic regions with evidence of parent-of-origin biased methylation on chromosome 16

Not shaded entries were found with blood-based analysis, gray-shaded entries with lung-based analysis. Abbreviations: int intron, ex exon, nc non-coding, AE
histone modification indicative of the active enhancer, b peripheral blood, f skin fibroblasts, l lung, n/a data not available
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Fig. 1 Parent-of-origin biased differential DNA methylation on chromosome 16. a Regions with preferential maternal methylation are written in
red font, those with paternal methylation in blue. Symbols next to gene names associated with differentially methylated regions indicate the
tissue in which the parent-of-origin biases in methylation could be observed (teardrop, blood; triangle, lung; diamond, fibroblast). b Differential
methylation at known imprinted locus ZNF597. Horizontal bars indicate known regions of differential methylation (red, maternal methylation;
blue, paternal methylation). c Differential methylation at suspected imprinted locus near PRR25 (pink horizontal bars). Differential methylation at
16q24.1 TLDC1/COTL1-intergenic locus (d) and CRISPLD2 (e). White areas in b–e indicated regions suggestive of parent-of-origin biased
methylation based on our analysis, gray-shaded areas fall outside these boundaries. Lines in b–e bottom panels were created using LOESS
smoothing with a span of 0.1, causing some data points to extend beyond the expected 0–100% methylation range. B blood, F fibroblast, L lung

Parent-of-origin biased methylation provides evidence for
imprinting of PRR25 in peripheral blood

Among the regions with suggestive evidence of parentof-origin biased methylation were two maternally methylated intergenic regions between PRR25 and LMF1 at
16p13.3 that were within 27 bp of each other (Table 1,
Fig. 1c). Although this locus has not been reported as
imprinted as consistently as ZNF597, data from previous
studies show maternal methylation at chr16:867,208–868,000
[21], chr16:866,647–868,075 [23], and chr16:867,075–
868,443 [24] overlapping the PRR25/LMF1 intergenic region
identified in our study. In addition, Jadhav et al. [18] presented evidence that PRR25 is paternally expressed in
lymphoblastoid cells, suggesting that methylation of the maternal allele at this locus could act as a suppressor of PRR25

expression in cis. We were unable to find any published information on LMF1 imprinting, potentially indicating that
the methylation at this locus, intergenic to PRR25 and
LMF1, might only affect PRR25. Furthermore, the methylation patterns in upd(16)mat fibroblast samples did not resemble those in maternal UPD blood samples, implying that
the methylation at this PRR25 locus might be tissue-specific.
Blood-based analysis reveals two small, tissue-specific loci
with evidence of parent-of-origin biased DNA methylation
on 16q24.1

In addition, we identified evidence for a small maternally
methylated region on 16q24.1 in blood cells (Table 1,
Fig. 1d). This differentially methylated intergenic region is flanked by TLDC1 (TBC/LysM-associated
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domain-containing protein 1) and COTL1 (coactosin
like F-actin binding protein 1), neither of which have been
associated with ACDMPV, regulation of FOXF1 expression, or causatively linked to any other Mendelian disorders. While DNA methylation levels were higher in
upd(16)mat relative to upd(16)pat and controls in peripheral blood samples, DNA methylation levels were lower in
the upd(16)mat fibroblast sample, suggesting that
parent-of-origin biased DNA methylation at this intergenic 16q24.1 locus might be tissue-specific.
We then sought to evaluate the methylation status of
this locus in lung tissues. We performed bisulfite sequencing on three lung tissue samples, one control and
two obtained from individuals with ACDMPV caused by
heterozygous, different-sized 16q24.1 deletions of the
maternally inherited chromosome 16. Consequent upon
the maternal deletion, one of the ACDMPV lung samples was hemizygous for the paternal chromosome at
the 16q24.1 TLDC1/COTL1-intergenic locus. We found
that at this locus, paternal DNA methylation levels in
lung tissue were high with intermediate methylation in
biparental controls (Fig. 1d). These results are in contrast to those seen in blood, indicating that the initially
identified methylation patterns at this TLDC1/COTL1
intergenic locus might be blood-specific. The differences
in methylation in lung tissue compared to blood, i.e., paternal > biparental methylation versus paternal < biparental < maternal methylation, might further indicate an
inversion of the parentally biased methylation patterns
between these tissues.
Given our particular interest in DMRs at 16q24.1, we next
took a closer look at regions on this chromosome band with at
least two, but fewer than five, neighboring differentially methylated CpG cytosines in peripheral blood samples that would
have been below filtering thresholds in our previous analyses.
Since SNVs occur frequently at CpG dinucleotides and can
obscure methylation calls [37, 38], we eliminated eight of these
smaller regions that were found to have SNVs at candidate
CpGs based on the variant calling results from our bisulfite sequencing data. We focused on those regions that (1) overlapped a hemizygous paternal allele in ACDMPV lung
samples, (2) showed resembling parent-of-origin biased
methylation in lung tissue, and (3) spanned more than one
CpG dinucleotide. Using this analytical approach, we identified one additional 16q24.1 region—chr16:84,867,676–
84,867,696—with evidence of parent-of-origin biased DNA
methylation in both blood and lung tissue. This locus
showed evidence of paternal DNA methylation at two
neighboring CpG dinucleotides located in the first intron of
CRISPLD2 (Fig. 1e), which encodes a cysteine-rich
secretory protein and has been associated with nonsyndromic cleft lip [39]. Upd(16)mat fibroblast DNA
methylation levels were high, in contrast to upd(16)mat
blood samples (Fig. 1e), indicating that the parent-of-origin
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methylation at this locus might be specific to blood and
lung tissue.
Lung-based analysis of 16q24.1 reveals evidence of
parent-of-origin biased DNA methylation

To find regions with parent-of-origin biased methylation
specific to lung tissue, which would not have been identified in the previous peripheral blood-based analyses,
we next studied DNA methylation at the maternally deleted locus, which exposes the remaining paternal allele,
in each of the two ACDMPV lung samples. Since the deleted segments in each sample do not overlap, we compared CpG methylation of the hemizygous segment
from each ACDMPV sample with those of the equivalent
dizygous segments from the remaining ACDMPV and
lung control samples. CpG methylation loci with a difference in percent methylation of at least 20 between
our case and each dizygous control were considered indicative of parent-of-origin biased DNA methylation. Interestingly, we did not identify any patterns matching our
criteria for parent-of-origin biased DNA methylation
within chr16:86,505,450–86,575,461, the smaller of the
two maternally deleted regions containing FOXF1, its
neighboring long noncoding RNA (lncRNA) FENDRR, or
their promoters. However, the larger deleted locus at
chr16:83,673,382–86,298,284, containing the FOXF1 enhancer, harbored eight intervals with evidence of
parent-of-origin biased methylation (Table 1, Additional
file 1: Table S3, Additional file 2: Fig. S3). One of these intervals overlapped an intron of the H-cadherin-encoding
gene CDH13 (Fig. 2a), for which aberrant promoter
methylation and consequent loss of gene expression have
been associated with non-small cell lung carcinoma [40].
Further, we identified a small intergenic region within 10
kb of the transcription start site of LINC01082 (Fig. 2b)—
a lncRNA which is thought to function as a transcriptional
regulator of FOXF1 and the loss of which has been associated with atypical ACDMPV [41].

Discussion
We studied the genomic methylation pattern of chromosome 16 at high-resolution to identify new loci with
parent-of-origin biased DNA methylation that might explain some of the phenotypic similarities between
upd(16)mat and ACDMPV as well as differences between upd(16)mat and upd(16)pat.
As a positive control and experimental validation of
our analytical approach, we confirmed known DMRs associated with ZNF597, the best-documented imprinted
gene on chromosome 16: the maternally methylated
locus mapping 0.5 kb telomeric to the ZNF597 gene and
the paternally methylated locus between ZNF597 and
NAA60, both on 16p13.3 [19–21]. We identified an additional maternally methylated interval in the ZNF597/

Schulze et al. Clinical Epigenetics

(2019) 11:60

Page 7 of 10

Fig. 2 Methylation patterns at new loci with evidence of parent-of-origin biased methylation in lung tissue. a DNA methylation at a region
overlapping CDH13. b DNA methylation at a region within 10 kb of LINC01082. White areas indicate regions suggestive of parent-of-origin biased
methylation based on our analysis, gray-shaded areas fall outside these boundaries. Top panels show DNA methylation in lung tissue samples;
bottom panels show DNA methylation in blood and fibroblast samples for comparison

NAA60 intergenic region, which is likely an extension of
the already known locus. Moreover, we have found further evidence in support of blood-specific maternal
methylation at PRR25 on 16p13.3 [18, 21, 23, 24]. However, the function and therefore potential pathogenic
relevance of PRR25 remains unknown.
A focused DNA methylation analysis of the hemizygous 16q24.1 region in lung tissue samples from individuals with ACDMPV caused by deletions of the maternal
allele of this region revealed a putatively paternally
methylated locus near LINC01082. LINC01082 is located
within the FOXF1 lung-specific upstream enhancer and
has been proposed to regulate FOXF1 expression [32,
41]. We hypothesize that parent-of-origin biased methylation of this site may contribute to differential expression of LINC01082 and thus differential expression of
FOXF1 as well. Functionality of this differentially methylated locus is additionally supported by the presence of
conserved binding sites for several transcription factors,
including lung-specific LUN1 [29].
Recently, based on qRT-PCR and bisulfite-PCR, Alsina
Casanova et al. [42] concluded that there was no evidence of imprinting at the 16q24.1 locus in lung tissue.
However, due to a lack of informative SNVs, allelic expression of LINC01082 was not assessed. Further, their differential methylation analyses relied upon mean methylation
levels of 20 CpGs, a window size with which differential
methylation of regions containing fewer CpGs, such as the
one near LINC01082, would not have been detected.
Nevertheless, they showed regions consistent with allelic
methylation in lung overlapping LINC01082 and noted

sperm-specific methylation across a ~ 250 kb region, including FOXF1 and its intronic enhancer [43], which appears to become mostly unmethylated in blastocysts. The
evidence of parent-of-origin biased DNA methylation
identified in the vicinity of LINC01082 could therefore be
a remnant of gamete-specific methylation that persisted
after preimplantation reprogramming, as is typically observed for germline derived DMRs. Alternatively, it could
reflect confinement of differentially methylated regions to
a small fraction of specialized lung cells.
In the analysis of ACDMPV lung samples, we also
identified evidence for a paternally methylated intergenic
interval between CRISPLD2 and ZDHHC7 on 16q24.1.
Of note, during a targeted analysis of the 16q24.1 region
in peripheral blood, we found a small locus in the first
intron of CRISPLD2 with evidence of paternal methylation that was also reflected in lung tissue. CRISPLD2 has
been reported in the context of non-syndromic cleft palate. While neither upd(16)mat nor ACDMPV individuals
present with cleft palate, it would be interesting to determine whether individuals with ACDMPV caused by
larger-sized deletions that span CRISPLD2 share specific
clinical phenotypes and how these phenotypes compare
to those commonly observed in individuals with
upd(16)mat.
Approximately 2 Mb centromeric to FOXF1, we found
a maternally methylated intergenic interval between
TLDC1 and COTL1. Sanchez-Delgado et al. [23] described two regions associated with TLDC1 that showed
gamete-specific methylation patterns—one at the TLDC1
promoter and the other intergenic to TLDC1 and
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COTL1, mapping approximately 13 kb upstream to our
candidate interval. Both regions are methylated in oocytes and unmethylated in sperm; however, differentiated
tissues appear to become fully methylated at the intergenic locus, while intermediate methylation levels are
maintained at the TLDC1 promoter locus. The maternally methylated TLDC1/COTL1 intergenic interval
identified in our study could be a remnant of the transient gamete-specific methylation observed in the genomic region surrounding TLDC1. Even though parentof-origin methylation in this region was specific to
blood, other tissues not sampled in the context of this
study, but relevant to the shared upd(16)mat and
ACDMPV phenotypes, could show a similar differential
methylation signature.
While we identified suggestive evidence of
parent-of-origin biases in DNA methylation at 16q24.1,
it is also possible that larger imprinted loci exist in this
region whose differential methylation might have been lost
later during embryonic development. Sanchez-Delgado
et al. [23] listed 17 regions on 16q24.1 that are methylated
in oocytes but not in sperm and showed intermediate
methylation levels in the blastocyst stage and often in the
placenta. The differentially methylated region closest to
FOXF1 was an intergenic locus at chr16:86,638,847–
86,639,716. If maternal methylation at these regions acts
as a repressor of gene expression and the tissues of early
development rely mostly on the expression of the paternal
allele, then pathogenic deletions of the maternal allele
causing ACDMPV would be of smaller consequence with
the potential to result in a live birth, whereas deletions of
the paternal allele would potentially have more severe
phenotypic/developmental consequences. Targeted analyses of 16q24.1 in germ cells and placental tissue might
provide more insight into a possibly transient nature of
the imprinting surrounding FOXF1.
Aside from the 16q24.1 loci described above, we found
additional regions on chromosome 16 in peripheral
blood with evidence for parent-of-origin biased methylation that might be of relevance to the upd(16)mat
phenotype, including a maternally methylated region
within the last intron of PMM2 on 16p13.2. PMM2 encodes phosphomannomutase-2 that has been associated
with congenital disorder of glycosylation type 1a (MIM
#212065). Among others, the features of this disorder include hypotonia, strabismus, encephalopathy, and cerebellar hypoplasia. According to the Encyclopedia of DNA
Elements (ENCODE), this differentially methylated region
overlaps a histone 3 lysine 27 acetylation (H3K27Ac) signature of active enhancers in H1 human embryonic stem
cells (hESCs), although the effect of altered DNA methylation on this regulatory activity is unclear.
The second region with evidence of parent-of-origin
biased methylation in peripheral blood at a Mendelian
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disease gene overlapped the last intron of the
WW-domain-containing oxidoreductase, WWOX, on
16q23.1, a gene associated with epileptic encephalopathy
(MIM #616211), esophageal squamous cell carcinoma
(MIM #133239), and spinocerebellar ataxia (MIM
#614322) inherited in the autosomal recessive manner.
Interestingly, the methylation pattern in this region appears nearly bimodal, with upd(16)pat samples showing
very low levels of methylation in contrast to both
upd(16)mat samples and biparental controls, which
showed higher levels of methylation. The atypical
parent-of-origin biased methylation at this locus might
be the result of favored high methylation levels in individuals with at least one maternally methylated template
allele, which could serve as a guide for the establishment
of methylation on the paternal allele in a hierarchical
fashion [44]; however, in the absence of such a template,
as is the case in upd(16)pat, the methylation levels might
remain low.
Our high-resolution bisulfite sequencing approach has
allowed us to closely examine regions of chromosome
16 that are not captured by the methylation arrays commonly used to study differential methylation, thereby
allowing us to identify novel regions with potential
parent-of-origin biased DNA methylation. Among our
candidate regions, we identified loci with evidence of
parent-of-origin DNA methylation on 16q24.1 that
might contribute to the clinical phenotypes shared between individuals with ACDMPV and upd(16)mat, but
also found support for novel differentially methylated
parental alleles at other loci. Further studies are needed
to validate parent-of-origin biased DNA methylation in
the newly identified candidate regions and to evaluate
their consequences on the expression of nearby genes.
In addition, with expanding sample sizes, we will be able
to address differences in methylation that may have resulted from age, gender, or cell type heterogeneity. Alternatively, phenotypic penetrance of some of UPD- or
16q24.1 hemizygosity-linked diseases, suggestive of genomic imprinting, could result also from differential histone 3 methylation and other epigenetic modifications.
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LOESS smoothing with a span of 0.1, causing some data points to extend
beyond the expected 0–100% methylation range. Abbreviations: B, blood;
F, fibroblast; L, lung. Figure S3. Differential methylation found through
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